多西紫杉醇联合顺铂每周给药治疗Ⅲ—Ⅳ期NSCLC 30例

目的：观察多西紫杉醇（DOC）联合顺铂（DDP）以每周给药方案治疗Ⅲ－Ⅳ期非小细胞肺癌（NSCLC）的临床疗效,生存期及毒副反应。方法：治疗Ⅲ-Ⅳ期SNCLC患者30例,DOC 25mg/m2静脉点滴1小时,第1,8,15天;DDP 25mg/m2静脉点滴,第1,8,15天,28天为一疗程,至少治疗二周期。结果：总有效率为43＝．4％（13／30）,均为部分缓解,对原发灶和转移灶均有较好疗效,Karnofsky计分增加或不变者占66．7％,中位缓解期为7月,生存年以上者占40％,主要毒副反应为骨髓抑制,Ⅲ-Ⅳ度白细胞下降占16．7％,III度血小板下降占6．7％,无III－IV度血红蛋白下降,非血液学性轻微,结论：DOC与DDP每周给药方案治疗NSCLC有较好疗效,耐受性。

Combination chemotherapy with docetaxel and cisplatin in weekly schedule in the treatment of 30 cases of advanced non-small cell lung cancer

Objective　To observe the response rate, survival time and toxicity of docetaxel and cisplatin in weekly schedule in the treament of stage Ⅲ-Ⅳ non-small cell lung cancer. Methods　A total of 30 cases of stage Ⅲ-Ⅳ non-small cell lung cancer was included in this study. Docetaxel 25*!mg／m2 and cisplatin 25*!mg／m2 were given through intravenous dripping for the 1st, 8th, and 15th days. The chemotherapy was repeated every 28 days. Each patient was given at least 2 cycles. Results　The overall response rate was 43.3％ (13／30,all were partial response). Quality of life of the patients was improved (there were 66.7％ of the patients with Karnofsky score increased or unchanged). Median remission duration was 7 months. 40％ of the patients survived for more than 1 year. The main toxicity was hematological: Grade Ⅲ-Ⅳ leucopenia was 16.7％; Grade Ⅲ thrombocytopenia was 6.7％. The non-hematological toxicity was mild. Conclusion　The regimen of docetaxel and cisplatin in weekly schedule is effective and tolerable in the treatment of non-small cell lung cancer.